These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34351305)

  • 1. Dual inhibition of FGFR4 and BCL-xL inhibits multi-resistant ovarian cancer with BCL2L1 gain.
    Guo T; Gu C; Li B; Xu C
    Aging (Albany NY); 2021 Aug; 13(15):19750-19759. PubMed ID: 34351305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.
    Stover EH; Baco MB; Cohen O; Li YY; Christie EL; Bagul M; Goodale A; Lee Y; Pantel S; Rees MG; Wei G; Presser AG; Gelbard MK; Zhang W; Zervantonakis IK; Bhola PD; Ryan J; Guerriero JL; Montero J; Liang FJ; Cherniack AD; Piccioni F; Matulonis UA; Bowtell DDL; Sarosiek KA; Letai A; Garraway LA; Johannessen CM; Meyerson M
    Mol Cancer Res; 2019 Nov; 17(11):2281-2293. PubMed ID: 31462500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.
    Ye Y; Jiang D; Li J; Wang M; Han C; Zhang X; Zhao C; Wen J; Kan Q
    Tumour Biol; 2016 Mar; 37(3):3185-95. PubMed ID: 26432329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer.
    Ramesh P; Di Franco S; Atencia Taboada L; Zhang L; Nicotra A; Stassi G; Medema JP
    Cell Rep; 2022 Feb; 38(7):110374. PubMed ID: 35172148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain of 20q11.21 in human embryonic stem cells improves cell survival by increased expression of Bcl-xL.
    Nguyen HT; Geens M; Mertzanidou A; Jacobs K; Heirman C; Breckpot K; Spits C
    Mol Hum Reprod; 2014 Feb; 20(2):168-77. PubMed ID: 24217388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
    Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer.
    Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN
    Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
    Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
    Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer.
    Zhang H; Xue J; Hessler P; Tahir SK; Chen J; Jin S; Souers AJ; Leverson JD; Lam LT
    Mol Cancer; 2015 Jul; 14():126. PubMed ID: 26134786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
    Weeden CE; Ah-Cann C; Holik AZ; Pasquet J; Garnier JM; Merino D; Lessene G; Asselin-Labat ML
    Oncogene; 2018 Aug; 37(32):4475-4488. PubMed ID: 29743589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
    Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
    Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATF3 Repression of BCL-X
    Chüeh AC; Tse JWT; Dickinson M; Ioannidis P; Jenkins L; Togel L; Tan B; Luk I; Davalos-Salas M; Nightingale R; Thompson MR; Williams BRG; Lessene G; Lee EF; Fairlie WD; Dhillon AS; Mariadason JM
    Clin Cancer Res; 2017 Sep; 23(18):5573-5584. PubMed ID: 28611196
    [No Abstract]   [Full Text] [Related]  

  • 14. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
    Mu P; Nagahara S; Makita N; Tarumi Y; Kadomatsu K; Takei Y
    Int J Cancer; 2009 Dec; 125(12):2978-90. PubMed ID: 19422046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
    Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.
    Brotin E; Meryet-Figuière M; Simonin K; Duval RE; Villedieu M; Leroy-Dudal J; Saison-Behmoaras E; Gauduchon P; Denoyelle C; Poulain L
    Int J Cancer; 2010 Feb; 126(4):885-95. PubMed ID: 19634140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation.
    Roidl A; Berger HJ; Kumar S; Bange J; Knyazev P; Ullrich A
    Clin Cancer Res; 2009 Mar; 15(6):2058-66. PubMed ID: 19240166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
    Blessing AM; Santiago-O'Farrill JM; Mao W; Pang L; Ning J; Pak D; Bollu LR; Rask P; Iles L; Yang H; Tran S; Elmir E; Bartholomeusz G; Langley R; Lu Z; Bast RC
    Cancer; 2020 Aug; 126(15):3579-3592. PubMed ID: 32484926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.